



## iTrack™ Canaloplasty to be Featured at the 2024 Women in Ophthalmology (WIO) Summer Symposium

**California, USA, July 23, 2024** – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that the Company's proprietary **iTrack™ canaloplasty technology** will be featured in the official scientific program of the 2024 Women in Ophthalmology (WIO) Summer Symposium, taking place in Carlsbad, California, August 22nd – 25th, 2024.

A summary of the iTrack™ posters at the WIO Summer Symposium is included below:

Analisa Arosemena (USA), David Lubeck (USA), Keith Barton (UK), Nathan Kerr (Australia)

### **24-Month Results of iTrack Global Data Registry to Support the Role of Canaloplasty for Treatment of Glaucoma**

*Session: Poster Session I*

*Monitor: 6*

*Date: Saturday, August 24 - Time: 11:05am - 11:50am*

Mary Qiu (USA), David Lubeck (USA), Keith Barton (UK), Nathan Kerr (Australia)

### **12-Month Outcomes of Ab-Interno Canaloplasty Combined with Phacoemulsification Across Different Glaucoma Types and Severities: the iTrack Global Data Registry (iTGDR)**

*Session: Poster Session I*

*Monitor: 5*

*Date: Saturday, August 24 - Time: 11:05am - 11:50am*

---

## **ABOUT NOVA EYE MEDICAL**

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include the iTrack™ portfolio of canaloplasty devices for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the



treatment of severe or complex glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

---

## **ABOUT CANALOPLASTY**

First introduced in 2008, canaloplasty is a surgical treatment for glaucoma that targets the main sites of outflow resistance in the conventional outflow pathway: the trabecular meshwork, Schlemm's canal, and the distal collector channels. Based on the same principles as angioplasty, a flexible microcatheter is cannulated 360 degrees around Schlemm's canal during the procedure to manually break and remove blockages. Next, viscoelastic fluid is injected into Schlemm's canal as the microcatheter is withdrawn to dilate the distal outflow system and to improve the function of the trabecular meshwork.

*The iTrack™ Advance canaloplasty device has a US Food and Drug Administration (FDA) 510(k) and CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma.*

*The iTrack™ Advance canaloplasty device has been cleared for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma.*

For additional information about canaloplasty and the *iTrack™ Advance*, including safety information, please visit: <https://itrack-advance.com>

For media enquiries, please contact:

Kate Hunt: Nova Eye Chief Commercial Officer - [khunt@nova-eye.com](mailto:khunt@nova-eye.com)

Giorgio Pirazzini: GP Communications – [giorgio@gpcommunications.eu](mailto:giorgio@gpcommunications.eu)